Rklb pre-earnings comprehensive analysis

RKLB — full pre-earnings workup

Print: Monday 10 Aug 2026, after the close. Consensus: EPS −$0.08, revenue $231.1M (company guided $225–240M). Last close $82.83 (Fri 07 Aug), market cap ~$47.9B.

Before anything else, let me challenge the framing of your question. You asked "what price should I pay" before a print with a 13.6% implied move. That's not a valuation decision, it's a coin flip on a binary event. And your premise that "high expectations" prints get punished is not what RKLB's own data says — the biggest run-up into a print produced the biggest gain. Details below.

---

1. How RKLB has actually reacted to earnings

Print	Run-up 30d into print	Gap at open	Day-1 close	Follow-through
07 Aug 2025	~flat (43.21→44.21)	+7.4%	+1.1%	faded, chopped 40–48
10 Nov 2025	−20% (65.42→51.90)	+7.9%	−1.3%	−12.3% over 3 days (51.90→45.54)
26 Feb 2026	−10% (80.48→72.65)	−6.8%	−4.9%	stabilized, then rallied
07 May 2026	+18% (66.32→78.58)	+9.5%	+34.2%	ran to $150.99 by 27 May

Next-day close change % for each of the last four RKLB reports.

What actually repeats: RKLB gaps up on the number three times out of four, and in two of those three the gap was fully sold (Aug'25 +7.4% gap → +1.1% close; Nov'25 +7.9% gap → −1.3% close, then −12% over three days). The reliable pattern is gap-and-fade, not "high expectations get punished." The one time it held the gap (May'26), the stock had momentum going in — it was above a rising 50-day. Right now it is below a steeply falling 50-day. That is the material difference from May.

---

2. Chart issues — and there are real ones

Level	Value	Note
Last close	82.83	RSI(14) 56.2
SMA 20	70.13	price well above
SMA 50	90.55	overhead, falling ~1.2/day
SMA 200	77.98	just below price
ATR(14)	6.66	~8% daily range

The problems:

1. Death cross is roughly 10 sessions away. That puts a 50/200 bearish cross around ~21 Aug 2026 unless price rips hard. That's a mechanical, well-telegraphed event that a lot of systematic money reacts to.

2. Relative strength collapsed and has only partially healed. Versus same-sector/same-market-cap peers, RKLB's quarterly RS percentile went 99 (late May) → 6.3 (29 Jul) → 41.9 (07 Aug). A drop from the 99th to the 6th percentile in nine weeks is textbook distribution, not a shakeout. The bounce to 42 is encouraging but it is not leadership.

3. The damage is severe. Peak $150.99 (27 May) → low $58.20 (29 Jul) = −61.5%. Current price is a +42% bounce in 7 sessions off that low — into resistance, before a catalyst. That is a bad risk/reward entry geometry regardless of your thesis.

4. Overhead supply is stacked. $83–86 (early-July shelf: 83.35, 82.55), then the falling 50-day at ~$88–90, then $93, then $100–102.

5. Unfilled gap below. 03 Aug high 70.60 → 04 Aug low 72.36 leaves an open gap at 70.60–72.36.

Support ladder: 77.98 (200-day) → 74.48–75.67 (shelf) → 70.60–72.36 (gap) → 64–67 → 58.20 (July low).

---

3. Options around the print

Implied move ≈ ±13.6%. Off $82.83 that's a $71.6 – $94.0 band. Term structure is brutally steep: ATM IV ~128–135% for 14 Aug vs ~91% for 18 Sep. Translation: if you buy front-week options and the move is anything less than 13.6%, IV crush eats you even if you pick the direction right.

Friday's flow was aggressively call-skewed on the earnings week: 14 Aug call volume 8.5K at $90, 5.0K at $100, 4.1K at $85, 3.2K at $80. Put volume was concentrated below — 2.1K at $50, 1.2K each at $70/$75. That is retail-style upside speculation, not institutional positioning.

The genuinely notable large trades:

Date	Contract	Premium	Read
06 Aug	21 Jan'28 $90 CALL	$9.1M at ask	Single biggest bet — long-dated, bullish, i.e. a Neutron bet, not an earnings bet
07 Aug	16 Oct'26 $75 PUT sweep	$626K at bid	Put selling — bullish/neutral
06 Aug	15 Jan'27 $75 PUT	$682K at bid	Put selling
05–06 Aug	Oct'26 / Dec'26 / Mar'27 $65 PUTs	~$1.1M combined, at ask	Genuine downside hedges at $65

Interpretation: the smart-money footprint is bullish on a 12–18 month horizon (the $9.1M Jan-2028 $90 call) while simultaneously buying $65 protection for Q4/Q1. Somebody is expressing exactly the view I'd hold: the long-term Neutron option is worth owning, the near term is dangerous. Nobody sizeable is betting on the print itself.

Short volume rose with the rally (5.1M of 24.2M total on 07 Aug ≈ 21%), so part of the bounce is hedging/shorting into strength, not pure demand.

---

4. Valuation — this is the weakest part of the story

RKLB trades at roughly 70x trailing sales. Industry median is 3.16x. It is the single most expensive name in its industry group on both P/S and EV/Sales (58.75x and 57.18x at Q1, both the maximum of the peer set), and on EV/Gross-Profit at 156x vs an industry median of 10.2x.

RKLB pays the highest sales multiple in the group. ASTS excluded — at 291x TTM sales it breaks the scale.

In fairness to the bulls: RKLB has the second-best gross margin in the group (38.2%), behind only PL, and it is expanding (32.1% → 36.9% → 38.0% → 38.2% over four quarters). Revenue grew +63.5% YoY in Q1. Backlog is $2.2B, +108% YoY. Balance sheet is genuinely strong: $1.4B cash vs $138.7M debt — net cash ~$1.34B, and management claims >$2B total liquidity.

But the things the bull case glosses over:

• Dilution is severe. Diluted shares went 505.6M (Q1'25) → 605.4M (Q1'26) = +19.7% in one year. You are being diluted at ~20%/yr. Revenue growing 63% while share count grows 20% is not the same as 63% per-share growth.
• Cash burn is accelerating, not shrinking: FCF −$77.4M (Q1'26), −$114.2M (Q4'25), −$69.4M (Q3'25). Management explicitly guided that burn "will remain elevated."
• Operating loss has not improved in two years. −$55.97M (Q1'26) vs −$43.08M (Q1'24). Revenue more than doubled; the operating loss got worse.
• Gross margin is guided DOWN for the quarter you're about to trade: 33–35% GAAP vs 38.2% delivered in Q1.
• At ~70x sales with negative FCF, there is no valuation floor. The price is a pure function of the Neutron narrative. That cuts both ways.

---

5. What competitors tell you

• SpaceX is now public and trading below its IPO price, with shares "extending their post-IPO decline" (27 Jul). This is the single most important read-across: the sector's anchor asset is de-rating, and that compresses everyone's multiple. Sector-wide selloffs on 13, 16, 24, 28 Jul were all attributed to SpaceX/peer weakness, not RKLB news.
• SpaceX now flies Starlink on ~80% of its flights and its own constellation is its biggest customer. That structurally helps Rocket Lab — third-party launch capacity is being squeezed out. It is the cleanest bull argument for Neutron demand.
• ASTS priced a $1B convertible in mid-July and the whole sector sold off on "debt dilution fears." Every capital raise in this sector is now treated as a sector-wide negative.
• The profitable comps are far cheaper. KTOS at 5.8x sales, AVAV at 5.0x — both with real revenue ($458.8M and $641.6M/qtr) and 22–32% gross margins. If you want defense-tech exposure without a 70x multiple, those exist. RKLB's premium is entirely payment for Neutron plus vertical integration.
• PL at 39x with 53.5% gross margins is the closest "expensive but high-margin" analogue.

---

6. What analysts will actually press on Monday

Straight from the Q1 call Q&A and the 10-K risk factors — these are the live issues:

1. Neutron Flight 1 timing. Cantor, TD Cowen and Wells Fargo all pushed on this. Management would only say "later this year" and explicitly refused to say early vs late Q4. Remember the Stage 1 tank ruptured in hydrostatic testing on 21 Jan 2026, which already hit the schedule. Any slip to 2027 is the single biggest de-rating risk. Watch for: test-stand milestones, LC-3 integrated testing, "Return on Investment" barge sea trials.
2. Gross margin trajectory. Citizens and Roth both drilled this. SDA Tranche 2/3 contracts are large but dilutive to gross margin, and Monaric adds ~$15M/qtr of below-average-margin revenue that needs "a lot of work." Guide is 33–35% GAAP. If they miss low, the margin-expansion story cracks.
3. Cash burn and further dilution. They raised $450.4M on the ATM in Q1 at an average of $70.47, plus a collared forward with a $63.61 floor and an $86.11 ceiling. The stock at $82.83 is sitting right under that ceiling. Expect questions on whether more equity is coming.
4. Golden Dome / Space-Based Interceptor sizing. Unquantified. CFO Spice said companies "have to put some of their own skin in the game to unlock a potentially very large opportunity" — i.e. RKLB spends its own cash first, with gates to clear. Analysts want a number; they won't get one.
5. Backlog conversion. Only 36% of the $2.2B backlog converts to revenue within 12 months. Bookings headlines are big; near-term revenue recognition is much smaller. Expect probing on Neutron ASPs (management is holding pricing, refusing to discount).
6. Government concentration. 47% of 2025 revenue from US government, top-5 customers = 49% of revenue, top-5 backlog customers = 77% of backlog, and all US government contracts are fixed-price (RKLB eats cost overruns). The Oct-2025 shutdown already caused award and payment delays.
7. Haste mix. Adam Spice's stated goal is 24 Haste launches/year as the margin base; currently 20–25% of the manifest. Progress here is the quiet margin lever.

One thing you should know that nobody advertises: insider selling has been heavy and one-directional. Peter Beck sold 3,275,779 shares for ~$286.4M across 06–08 Jul 2026 — right as the stock broke from $100 down to $83 — leaving 1,724,221 common shares. Kampani, Klein, Spice, Clevenger and Slusky all sold heavily in late May at $140–150. There is not a single open-market insider purchase in the last six months. These may well be pre-planned 10b5-1 sales, and I can't confirm either way, but the size and the timing relative to the top deserve your attention.

---

7. Scenarios and levels

These are scenarios, not forecasts. Street context: of the 13 firms with current targets, median $120, average $110.85; range from Wells Fargo's $60 (hold) and Piper's $83 (neutral, initiated 16 Jul) to Keybanc's $135. Piper's initiation thesis was literally "one-year gains are already priced in."

Horizon	Bear	Base	Bull
1 month (~10 Sep)	65–72 (fade the gap, death cross triggers)	76–90 (chop between 200-day and falling 50-day)	94–102 (gap holds, reclaims 50-day)
6 months (~Feb 2027)	45–58 (Neutron slips to 2027 + sector de-rate)	85–110	130–150 (Neutron flies, soft splashdown succeeds)
12 months (~Aug 2027)	40–55	100–125 (in line with street median)	160–185 (Neutron in revenue service + reuse proven)

Buy zones I'd actually watch (in ascending order of quality):

• $77–78 — 200-day SMA. First real test. Weakest of the three.
• $70.5–72.5 — unfilled gap + the 74.48/75.67 shelf just above. Best confluence.
• $64–67 — prior consolidation base.
• $58 — July low. If this breaks, the entire 2026 uptrend is gone and the thesis needs re-underwriting from scratch.

Sell / trim zones:

• $88–91 — falling 50-day. Highest-probability rejection point.
• $100–102 — early-July breakdown pivot.
• $135–150 — the May distribution zone. Full exit territory.

On "what price should I pay": I'm not going to hand you a number, because at 70x sales with negative and worsening free cash flow there is no defensible intrinsic anchor — you'd be buying a narrative, and the honest answer is that the entry price matters far less than whether Neutron flies. What I will say plainly: buying at $82.83 the day before a ±13.6% implied-move print, into a falling 50-day, after a +42% seven-day bounce, with an imminent death cross and zero insider buying, is the worst risk/reward geometry the chart has offered in six weeks. If you want the position, the disciplined path is to size small now and keep dry powder for $70–78, or simply wait for the print and buy the reaction rather than the anticipation. The one piece of genuine smart-money conviction in the data — that $9.1M January-2028 $90 call — is a long-dated bet, not an earnings bet. That's a hint about the right time frame.

I can't make this decision for you, and none of the above is trading advice. Position sizing and risk tolerance are yours alone.

---

Want me to create multi-factor alerts on RKLB for the key levels — a break above the falling 50-day (~$90), a reclaim/loss of the 200-day at $78, and the $70.6–72.4 gap zone? I can also set an alert that fires when RKLB's 50-day SMA crosses below its 200-day SMA so you catch the death cross the day it happens, or scan the space and defense-tech group for names with better relative strength than RKLB right now.